<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02913131</url>
  </required_header>
  <id_info>
    <org_study_id>159517</org_study_id>
    <secondary_id>R01CA183071</secondary_id>
    <nct_id>NCT02913131</nct_id>
  </id_info>
  <brief_title>Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies</brief_title>
  <official_title>Hyperpolarized C-13 Pyruvate as a Biomarker of PI3K/mTOR Pathway Inhibition in Patients With Advanced Solid Tumor Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rahul Aggarwal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center prospective imaging study investigating the utility of hyperpolarized
      C-13 pyruvate as a Biomarker of PI3K/mTOR pathway inhibition in patients with advanced solid
      tumor malignancies. The current protocol will serve as a companion imaging biomarker study
      paired with therapeutic trials of PI3K/mTOR pathway inhibitors (e.g. CUDC-907, BYL719), as
      well as a stand-alone protocol for patients treated with standard-of-care therapies
      inhibiting the PI3K/mTOR signaling pathway (eg. everolimus).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center prospective imaging study investigating the utility of hyperpolarized
      C-13 pyruvate/metabolic MR imaging. The current protocol will serve as a companion imaging
      biomarker study paired with therapeutic trials of PI3K/mTOR pathway inhibitors (e.g.
      CUDC-907, BYL719), as well as a stand-alone protocol for patients treated with
      standard-of-care therapies inhibiting the PI3K/mTOR signaling pathway (eg. everolimus).

      In Part A (run-in feasibility phase), patients will undergo imaging at a single time point,
      without paired tumor biopsy. There will be no follow up imaging or requirement for treatment
      with PI3K/mTOR pathway inhibitor. Iterative adjustment of radiofrequency coil geometry and
      imaging sequences will be undertaken to optimize intra-tumoral hyperpolarized
      pyruvate/lactate signal-to-noise ratio with the goal of achieving signal-to-noise ratio of at
      least 10 in a minimum of 3 patients in order to proceed to Part B of the study.

      In part B, patients will undergo paired baseline hyperpolarized C-13 pyruvate imaging + tumor
      biopsy,then initiate treatment with agent inhibiting the PI3K/mTOR pathway. After 21 days
      (+/- 14 days), patients will undergo repeat hyperpolarized C-13 pyruvate MR imaging + tumor
      biopsy. Patients will subsequently be treated with PI3K/mTOR pathway inhibitor until disease
      progression, unacceptable toxicity, or patient/physician decision to discontinue therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Signal-to-noise ratio with respect to intra-tumoral hyperpolarized C-13 lac/pyr ratio detected within target liver metastasis in patients with advanced solid tumor malignancies.</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Mean percent change from baseline in peak intra-tumoral hyperpolarized lactate/pyruvate ratio after initiation of treatment with PI3K/mTOR pathway inhibitor.</measure>
    <time_frame>Baseline and after approximately 21 days of therapy. Follow-up for approximately 6 months</time_frame>
    <description>Descriptive statistics will be used to characterize the mean change from baseline in intra-tumoral HP pyruvate/lactate ratio for the study cohort, along with 95% confidence interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events as graded by Common Toxicity Criteria version 4.0</measure>
    <time_frame>Throughout study - from baseline, after 21 days of therapy, and for duration of follow-up (approximately 6 months)</time_frame>
    <description>Safety analyses will be performed for all patients having received a dose of HP C-13 pyruvate. The study will use the NCI CTCAE v4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between percent change from baseline in peak intra-tumoral HP lactate/pyruvate ratio on metabolic MR imaging with clinical benefit rate (Part B)</measure>
    <time_frame>From baseline to approximately 21 days of therapy. Follow-up for approximately 6 months</time_frame>
    <description>For the purposes of analyzing the association between percent change from baseline in intra-tumoral peak lactate/pyruvate ratio on HP MRI with subsequent clinical outcomes, the cohort will be dichotomized by the median percent change. The objective response rate by RECIST 1.1 criteria and clinical benefit rate (response or stable disease for &gt; 24 weeks) will be compared between dichotomized groups using the chi-squared test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between percent change from baseline in peak intra-humoral HP lactrate/pyruvate ratio on metabolic MR imaging with progression-free survival (Part B)</measure>
    <time_frame>From baseline to approximately 21 days of therapy. Follow-up for approximately 6 months</time_frame>
    <description>The log rank test will be used to compare the radiographic progression-free survival between the two groups.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Association between HP peak lactate/pyruvate signal with immunohistochemical expression level of markers of PI3K/mTOR and glycolytic pathway, including LDH, phosphorylated S6, and phosphorylated Akt. (Part B)</measure>
    <time_frame>From baseline to approximately 21 days of therapy. Follow-up for approximately 6 months</time_frame>
    <description>Analyses will be performed to compare the HP MR markers with immunohistochemical and enzyme expression and activity data from biopsy tissue to investigate the molecular and physiological underpinnings of the HP 13C MR data. When both the HP biomarker and molecular biomarker (LDHA activity) are continuous variables, Spearman's rank correlation coefficient will be used to investigate a possible correlation between them. If the outcome is categorical (e.g. immunohistochemistry score 0-1+ vs 2-3+ for pS6, pAkt, LDHA, and MCT 1/4 expression), the HP biomarker distributions will be compared between the two categories using the Mann-Whitney test.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Part A: Feasibility Run-In</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with advanced solid tumor malignancies with at least one liver metastasis will be enrolled with iterative adjustment of coil design to optimize imaging parameters including spatial resolution and signal-to-noise ratio (SNR) of hyperpolarized pyruvate / lactate within the target metastatic lesion(s). The target SNR of 10 must be achieved in at least 3 patients in order to proceed to part B of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Biomarker Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with advanced solid tumor malignancies and the presence of at least one liver metastasis amenable to hyperpolarized C-13 pyruvate metabolic MR imaging who are planning on being treated with agent targeting PI3K/mTOR pathway will be enrolled.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyruvate (13C)</intervention_name>
    <description>Pyruvate injection followed by an MRI scan.</description>
    <arm_group_label>Part A: Feasibility Run-In</arm_group_label>
    <arm_group_label>Part B: Biomarker Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>MRI scan following the pyruvate (13c) injection</description>
    <arm_group_label>Part A: Feasibility Run-In</arm_group_label>
    <arm_group_label>Part B: Biomarker Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of at least one target liver lesion detected by standard staging scans that,
             in the judgment of Study Investigators, would be amenable to hyperpolarized C-13
             pyruvate/metabolic MR imaging: Target lesion must measure 1.5 cm in long axis diameter
             on CT or MRI

          -  The subject is able and willing to comply with study procedures and provide signed and
             dated informed consent.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

          -  Adequate organ function, including creatinine &lt; 1.5 x ULN or estimated creatinine
             clearance 50 mL/min (by the Cockcroft Gault equation) and total bilirubin &lt;3x ULN.

        Part B only:

          -  Presence of at least one target lesion amenable to percutaneous tumor biopsy in the
             judgment of Interventional Radiology

          -  No prior local therapy to target liver lesion.

          -  No history of bleeding diathesis.

          -  Patients on anti-coagulation they must be able to safely stop treatment for purposes
             of tumor biopsy.

          -  Planned treatment with agent targeting PI3K/mTOR pathway (either standard of care or
             investigational agent)

        Exclusion Criteria:

          -  Patients who because of age, general medical or psychiatric condition, or physiologic
             status cannot give valid informed consent.

          -  Patients unwilling or unable to undergo MR imaging, including patients with
             contra-indications to MRI, such as cardiac pacemakers or non-compatible intracranial
             vascular clips.

          -  Metallic implant or device that distorts local magnetic field and compromises the
             quality of MR imaging.

          -  Poorly controlled hypertension, defined as systolic blood pressure at study entry
             greater than 160 mm Hg or diastolic blood pressure greater than 100 mm Hg. The
             addition of anti-hypertensives to control blood pressure is allowed.

          -  Congestive heart failure or New York Heart Association (NYHA) status â‰¥ 2.

          -  A history of clinically significant EKG abnormalities, including QT prolongation (QTcF
             &gt; 500 ms), a family history of prolonged QT interval syndrome, or myocardial
             infarction (MI) within 6 months of study entry. Patients with rate-controlled atrial
             fibrillation/flutter will be allowed on study.

          -  Any condition that, in the opinion of the Principal Investigator, would impair the
             patient's ability to comply with study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rahul Aggarwal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rahul Aggarwal, MD</last_name>
    <phone>877-827-3222</phone>
    <email>cancertrials@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kamran Abri-Lavasani</last_name>
    <phone>877-827-3222</phone>
    <email>cancertrials@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rahul Aggarwal, MD</last_name>
      <phone>877-827-3222</phone>
      <email>cancertrials@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kamran Abri-Lavasani</last_name>
      <phone>877-827-3222</phone>
      <email>cancertrials@ucsf.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2016</study_first_submitted>
  <study_first_submitted_qc>September 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2016</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Rahul Aggarwal</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

